Keyphrases
Advanced Fibrosis
10%
Antiretroviral Therapy
10%
Chronic Hepatitis C
21%
Chronic Liver Disease
17%
Cirrhosis
25%
Confidence Interval
10%
Direct-acting Antivirals
16%
Fibrosis
13%
Fulminant Hepatic Failure
14%
Genotype 1
15%
Grazoprevir
14%
Hepatic Fibrosis
11%
Hepatic Injury
16%
Hepatitis B
20%
Hepatitis B Surface Antigen (HBsAg)
20%
Hepatitis B Virus
37%
Hepatitis B Virus DNA
19%
Hepatitis B Virus Infection
38%
Hepatitis C Virus
52%
Hepatitis C Virus Genotypes
20%
Hepatitis C Virus Infection
39%
Hepatitis E Virus
11%
Hepatocellular Carcinoma
20%
Immune Response
11%
Interferon-α (IFN-α)
12%
Ischemia
13%
Ischemia-reperfusion Injury
27%
Israel
36%
Israeli
12%
Lamivudine
36%
Lamivudine Resistance
13%
Liver
40%
Liver Allograft
11%
Liver Biopsy
21%
Liver Disease
15%
Liver Fibrosis
13%
Liver Transplant Recipients
53%
Liver Transplantation
100%
Mouse Liver
12%
Non-alcoholic Fatty Liver Disease (NAFLD)
27%
Nonalcoholic Steatohepatitis
23%
Orthotopic Liver Transplantation
15%
Primary Sclerosing Cholangitis
12%
Recurrent Hepatitis
13%
Ribavirin
19%
Serum Hepatitis
12%
Sofosbuvir
10%
Sustained Virological Response
15%
SVR12
15%
Transplantation
22%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
19%
Alanine Aminotransferase
10%
Antiviral Therapy
10%
Antivirus Agent
22%
Autoimmune Hepatitis
8%
Caspase 3
17%
Chronic Hepatitis B
13%
Chronic Hepatitis C
23%
Chronic Liver Disease
10%
Disease
10%
Erythropoietin
8%
Fatty Liver
6%
Fibrosis
25%
Fulminant Hepatic Failure
9%
Grazoprevir
14%
Hepatitis B
47%
Hepatitis B Antigen
18%
Hepatitis B Virus
48%
Hepatitis B(e) Antigen
6%
Hepatitis C
33%
Hepatitis C Virus
43%
Hepatitis C Virus Genotype 1
20%
Hepatitis Delta Virus
9%
Infection
42%
Injury
11%
Interferon
9%
Ischemia
18%
Lamivudine
37%
Lipopolysaccharide
6%
Liver Cell Carcinoma
13%
Liver Cirrhosis
20%
Liver Disease
10%
Liver Enzyme
10%
Liver Fibrosis
24%
Liver Injury
21%
Liver Ischemia
10%
Mouse
29%
Nonalcoholic Fatty Liver
22%
Placebo
16%
Prevalence
28%
Receptor
8%
Recombinant Erythropoietin
8%
Reperfusion Injury
25%
Ribavirin
21%
Ruzasvir
8%
Sofosbuvir
11%
Tumor Necrosis Factor
7%
Uprifosbuvir
8%
Virus DNA
13%
Virus RNA
7%
Medicine and Dentistry
Adverse Event
7%
Alanine Aminotransferase
6%
Alkaline Phosphatase
7%
Antiviral Therapy
14%
Antivirus Agent
11%
Ascites
7%
Bilirubin
6%
Brain Disease
8%
Cholestasis
12%
Chronic Hepatitis B
10%
Chronic Hepatitis C
15%
Chronic Liver Disease
13%
Disease
19%
Fibrosis
24%
Fulminant
6%
Fulminant Hepatic Failure
10%
Hepatitis B
44%
Hepatitis B Antigen
11%
Hepatitis B Virus
36%
Hepatitis B(e) Antigen
7%
Hepatitis C
23%
Hepatitis C Virus
37%
Hepatitis C Virus Genotype 1
8%
Hepatocellular Carcinoma
18%
Hepatocyte
9%
Infection
37%
Ischemia
6%
Kidney Transplantation
9%
Lamivudine
31%
Lipopolysaccharide
6%
Liver Biopsy
19%
Liver Cirrhosis
21%
Liver Disease
24%
Liver Enzyme
9%
Liver Fibrosis
21%
Liver Graft
28%
Liver Injury
12%
Liver Transplantation
83%
Nonalcoholic Fatty Liver
26%
Prevalence
20%
Primary Biliary Cirrhosis
10%
Primary Sclerosing Cholangitis
9%
Programmed Cell Death
7%
Recurrent Disease
8%
Reperfusion Injury
7%
Ribavirin
15%
Transplantation
12%
Vein Occlusion
8%
Virus DNA
10%
Virus Infection
6%